Navigation Links
Audentes Therapeutics to Present at the ARM 5th Annual Cell & Gene Therapy Investor Day
Date:4/17/2017

SAN FRANCISCO, April 17, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Matthew R. Patterson, President and Chief Executive Officer, will present a corporate overview at the Alliance for Regenerative Medicine's 5th Annual Cell & Gene Therapy Investor Day in Boston, MA.  The presentation is scheduled for Thursday, April 27, 2017, at 9:55 am ET.

To access a live webcast of the presentation, please visit the Events & Presentations page within the Investors & News section of the Audentes website.  Replays of live webcasts will be available on the Audentes website for approximately 30 days following the conference.

About Audentes Therapeutics, Inc.

Audentes Therapeutics (Nasdaq: BOLD) is a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases.  We have four product candidates in development, AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM), AT342 for the treatment of Crigler-Najjar Syndrome, AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).  We are a focused, experienced and passionate team committed to forging strong, global relationships with the patient, research and medical communities.

For more information regarding Audentes, please visit www.audentestx.com.

Audentes Contacts:
Investor Contact:
Thomas Soloway, CFO
415.818.1040
ir@audentestx.com

Media Contact:
Jeffrey Gruis
415.818.1015
media@audentestx.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/audentes-therapeutics-to-present-at-the-arm-5th-annual-cell--gene-therapy-investor-day-300440070.html


'/>"/>
SOURCE Audentes Therapeutics, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Audentes Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
2. Amarantus Forms Subsidiaries "Elto Pharma" to Focus on CNS Disorders and "MANF Therapeutics" to Focus on Ophthalmology
3. Nektar Therapeutics Presents New Preclinical Data for its Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting
4. United Therapeutics Announces Decision From Patent Trial And Appeal Board And Issuance Of New Patents
5. Viking Therapeutics to Present at H.C. Wainwright & Co.s 1st Annual NASH Investor Conference
6. Biotech Stocks on Investors Radar -- Portola Pharma, OvaScience, Ocera Therapeutics, and Ocular Therapeutix
7. Leading Alzheimer’s Expert Joins T3D Therapeutics’ Advisory Board
8. Biotech Stocks Under Scanner -- BioDelivery Sciences, Sage Therapeutics, Benitec Biopharma, and OncoGenex Pharma
9. Oramed to Present at Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference on March 28, 2017
10. FACIT Announces Investment in Propellon Therapeutics
11. Avexegen Therapeutics Announces Exclusive License Agreement with Children’s Hospital Los Angeles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... San Diego-based ... of its corporate rebranding initiative announced today. The bold new look is part ... as the company moves into a significant growth period. , It will also expand ...
(Date:10/10/2017)... firm Parks Associates announced today that Tom Kerber , ... Meeting , October 11 in Scottsdale, Arizona . Kerber ... smart safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase Driver ... "The residential security market has experienced continued growth, and the introduction ...
(Date:10/9/2017)... 2017  BioTech Holdings announced today identification and ... ProCell stem cell therapy prevents limb loss in ... demonstrated that treatment with ProCell resulted in more ... compared to standard bone marrow stem cell administration.  ... reduction of therapeutic effect.  ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... medical journal, Epilepsia, Brain Sentinel’s SPEAC® System which uses the surface electromyography ... generalized tonic-clonic seizures (GTCS) using surface electromyography (sEMG). The prospective multicenter phase ...
Breaking Biology Technology:
(Date:4/6/2017)... April 6, 2017 Forecasts by ... Document Readers, by End-Use (Transportation & Logistics, Government & ... Gas & Fossil Generation Facility, Nuclear Power), Industrial, Retail, ... Are you looking for a definitive report ... ...
(Date:4/4/2017)... 2017   EyeLock LLC , a leader of ... States Patent and Trademark Office (USPTO) has issued U.S. ... of an iris image with a face image acquired ... company,s 45 th issued patent. ... given the multi-modal biometric capabilities that have recently come ...
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities and ... and behavioral), by technology (fingerprint, AFIS, iris recognition, facial ... and others), by end use industry (government and law ... financial and banking, and others), and by region ( ... , Asia Pacific , and the ...
Breaking Biology News(10 mins):